Dear Sir,
The genetic basis of a familial form of primary aldosteronism, that is glucocorticoid-remediable aldosteronism (GRA) or familial hyperaldosteronism type I (FH-I), has been identified in an inherited chimeric gene resulting from unequal crossing-over between the 11b-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes. 1 A different form of familial aldosteronism with probable autosomal dominant inheritance, characterized by lack of aldosterone suppressibility by glucocorticoids and associated with bilateral adrenocortical hyperplasia or aldosterone-producing adenomas (APAs), has been also described (familial hyperaldosteronism type II, FH-II). 2 The molecular basis of FH-II is unclear. While defects in the angiotensin II receptor type 1 gene as well as in the CYP11B2 gene were excluded, 3, 4 linkage analysis in large FH-II families has recently shown a genetic association with chromosome region 7p22. 5, 6 Aldosterone-producing tumours have been also reported as part of the familial MEN1 syndrome. 7 We previously described 8 two pairs of sisters, from different families, with nonglucocorticoid-remediable aldosteronism, in whom one sibling from each pair had bilateral adrenal hyperplasia; in the other two sibs, blood pressure and potassium normalization was observed after removal of their unilateral APAs. In all four patients, no CYP11B1/CYP11B2 chimeric gene, 9 described in a single FH-II family, 10 no polymorphic variants of CYP11B2 gene, and no tumoral mutations of CYP11B1 gene were detected.
In the two patients with APAs, we evaluated the possibility that mutations of genes with tumour suppression properties, located either at the 7p22 or at the 11q13 region, which includes the MEN1 gene, were involved in the pathogenesis of adrenal neoplasia and aldosterone overproduction. In fact, assuming that development of adrenal tumours in our FH-II patients conforms to the 'two-hit' model of tumorigenesis, 11 a somatic mutation in an adrenal cell already deficient in one copy of a tumour suppressor gene via germ cell line inheritance (representing the first 'hit'), would be expected. For this purpose, loss of tumoral heterozygosity at chromosome 7p22 was assessed in the DNA from paired blood/adrenal samples by using five polymorphic microsatellite markers (D7S531, D7S616, D7S2521, D7S511, D7S517) covering at least 5 cM of genetic distance. Chromosome 11q13 was analysed with 3 MEN1-linked microsatellite markers (PYGM, D11S4946, D11S4933) and the intragenic polymorphism D418D. Silver staining of polyacrylamide gels after PCR marker amplification 12 showed that heterozygosity was retained with all microsatellites (except D7S616, non informative due to homozygosis, in one case) at the 7p22 and 11q13 regions in both APAs examined. Screening of germline mutations of MEN1 gene 13 confirmed lack of DNA sequence alterations.
Our findings of no allelic losses at 7p22 and 11q13 in APAs of two patients with FH-II belonging to unrelated families suggest that mutations of tumour suppressor genes located in these chromosome regions are not involved in the adrenal tumour development. The examination of known genes of the region 7p22 by Lafferty et al 5 has not shown any gene obviously related to aldosterone synthesis or functioning as tumour suppressor. Since then, other genes involved in human tumours but without tumor suppression properties, such as the check point MAD1L1 gene 14 (OMIM 602686), have been found in the region 7p22. Many unknown genes involved in tumorigenesis, however, could be located in the same region. In addition, loss of function in tumour DNA in spite of using close multipoint analysis, or gene promoter hypermethylation 15 cannot be excluded. The same limitations pertain to the 11q13 region, except than for the MEN1-gene. In fact, in accordance with other reports, 4 
